A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features

被引：0
|
作者：
Corn, Paul Gettys [1 ]
Tu, Shi-Ming [1 ]
Zurita, Amado J. [1 ]
Araujo, John C. [1 ]
Pagliaro, Lance C. [1 ]
Logothetis, Christopher [1 ]
Aparicio, Ana [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.148
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
148
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC)
    Kim, Joseph W.
    McKay, Rana R.
    Taplin, Mary-Ellen
    Davis, Nancy B.
    Monk, Paul
    Appleman, Leonard Joseph
    Lara, Primo
    Vaishampayan, Ulka N.
    Zhang, Jingsong
    Paul, Asit K.
    Bubley, Glenn
    Van Allen, Eliezer Mendel
    Huang, Ying
    Zhang, Zhenwei
    Loda, Massimo
    Shapiro, Geoffrey
    LoRusso, Patricia
    Ivy, S. Percy
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
    Graff, Julie Nicole
    Cheng, Heather H.
    Vuky, Jacqueline
    Alumkal, Joshi J.
    Kreitner, Dustin
    Petreaca, Delia
    Grivas, Petros
    Schweizer, Michael Thomas
    Higano, Celestia S.
    Chen, Yiyi
    Yu, Evan Y.
    Beer, Tomasz M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer
    Slovin, Susan F.
    Knudsen, Karen
    Halabi, Susan
    de Leeuw, Renee
    Shafi, Ayesha
    Kang, Praneet
    Wolf, Steven
    Luo, Bin
    Gopalan, Anuradha
    Curley, Tracy
    Fleming, Mark
    Molina, Ana
    Fernandez, Celina
    Kelly, Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (32) : 5015 - +
  • [4] Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).
    McKay, Rana R.
    Radke, Marc R.
    Shyr, Yu
    Zhao Shilin
    Taplin, Mary-Ellen
    Davis, Nancy B.
    Monk, Paul
    Appleman, Leonard Joseph
    Lara, Primo Lucky N.
    Vaishampayan, Ulka N.
    Zhang Jingsong
    Paul, Asit K.
    Bubley, Glenn
    Huang Ying
    Shapiro, Geoffrey
    LoRusso, Patricia
    Ivy, Percy S.
    Petrylak, Daniel Peter
    Swisher, Elizabeth M.
    Kim, Joseph W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [5] Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer
    Nozawa, Masahiro
    Mukai, Hirofumi
    Takahashi, Shunji
    Uemura, Hiroji
    Kosaka, Takeo
    Onozawa, Yusuke
    Miyazaki, Jun
    Suzuki, Kazuhiro
    Okihara, Koji
    Arai, Yoichi
    Kamba, Tomomi
    Kato, Masashi
    Nakai, Yasutomo
    Furuse, Hiroshi
    Kume, Haruki
    Ide, Hisamitsu
    Kitamura, Hiroshi
    Yokomizo, Akira
    Kimura, Takahiro
    Tomita, Yoshihiko
    Ohno, Keiji
    Kakehi, Yoshiyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (05) : 1026 - 1034
  • [6] Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer
    Masahiro Nozawa
    Hirofumi Mukai
    Shunji Takahashi
    Hiroji Uemura
    Takeo Kosaka
    Yusuke Onozawa
    Jun Miyazaki
    Kazuhiro Suzuki
    Koji Okihara
    Yoichi Arai
    Tomomi Kamba
    Masashi Kato
    Yasutomo Nakai
    Hiroshi Furuse
    Haruki Kume
    Hisamitsu Ide
    Hiroshi Kitamura
    Akira Yokomizo
    Takahiro Kimura
    Yoshihiko Tomita
    Keiji Ohno
    Yoshiyuki Kakehi
    International Journal of Clinical Oncology, 2015, 20 : 1026 - 1034
  • [7] A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC).
    Corn, Paul Gettys
    Tu, Shi-Ming
    Zurita, Amado J.
    Subudhi, Sumit Kumar
    Araujo, John C.
    Kim, Jeri
    Jonasch, Eric
    Pagliaro, Lance C.
    Siefker-Radtke, Arlene O.
    Wang, Jennifer
    Wang, Xuemei
    Heath, Elisabeth I.
    Logothetis, Christopher
    Aparicio, Ana
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC)
    Tralongo, P.
    Bordonaro, S.
    Di Lorenzo, G.
    Borsellino, N.
    Facchini, G.
    Rossetti, S.
    Martelli, V.
    Longo, V.
    Tralongo, A. C.
    Caspani, F.
    Tuzi, A.
    Spada, M.
    Calvani, N.
    Carlini, P.
    De Giorgi, U. F. F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [10] Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Dorff, Tanya B.
    Quinn, David, I
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan
    Kuhn, Peter
    Gross, Mitchell E.
    CLINICAL GENITOURINARY CANCER, 2019, 17 (04) : 241 - +
12345